Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 35,388 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Dysbiosis, Sarcopenia, Colon Cancer
Interventions: Standard Diet, BIG MACS Diet; Dietary Supplement
Lead sponsor: University of Minnesota; Other
Eligibility: 25 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: Treatment A (rosuvastatin), Treatment B (LX4211), Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly); Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy, no Evidence of Disease
Interventions: retinoid 9cUAB30, placebo, pharmacological study, laboratory biomarker analysis, cancer prevention; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Treatment of Hepatitis C
Interventions: Ledipasvir/Sofosbuvir FDC; Drug
Lead sponsor: Peter J. Ruane, M.D., Inc.; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Edematous Skin
Interventions: collagenase clostridium histolyticum (CCH); Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Coral Gables, Florida • Miami, Florida • New York, New York

Conditions: Intracerebral Hemorrhage, Ischemic Stroke
Interventions: Glycerly Trinitrate; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 2
States / cities: Los Alamitos, California • Los Angeles, California

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Potassium estimation algorithm; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Aspergillosis/Blood, Aspergillosis/Invasive
Interventions: micafungin, voriconazole; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 2 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 44
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 41 more

Conditions: Healthy
Interventions: Orforglipron, Midazolam, Quinidine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: Daridorexant; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Vision, Healthy, Attention
Interventions: Mixed trials, Blocked Trials; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
Interventions: CEP-701 (Lestaurtinib); Drug
Lead sponsor: Ronald Hoffman; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 7
States / cities: Palo Alto, California • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more

Conditions: Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal Hemicrania
Interventions: Exparel (Bupivacaine Liposome), Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy Volunteers
Interventions: LY2484595, Placebo, Moxifloxacin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 2
States / cities: Daytona Beach, Florida • Evansville, Indiana

Conditions: Tinnitus
Interventions: noise sound stimulation (Tucker-Davis Technologies), body electrical stimulation (Digitimer device), transcranial magnetic stimulation (Magstim); Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Gastric Motility Disorder
Interventions: Methylnaltrexone only, Codeine only, Methylnaltrexone + codeine, Placebo + placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Clostridium Difficile Colitis
Interventions: CRS3123, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bipolar Disorder, Depression
Interventions: PF-04455242; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 3
States / cities: New Haven, Connecticut

Conditions: Non-Small-Cell Lung Carcinoma, Adenocarcinoma
Interventions: Bevacizumab, Carboplatin, Paclitaxel, AG-013736 (axitinib); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 22
States / cities: Baton Rouge, Louisiana • Pittsfield, Massachusetts • Columbus, Mississippi + 14 more

Conditions: Healthy Participants
Interventions: Afimetoran, Phenytoin, Midazolam; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diabetic Foot Ulcer
Interventions: NuShield; Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 9
States / cities: Carlsbad, California • Fresno, California • Los Angeles, California + 6 more

Conditions: Lupus Erythematosus, Systemic
Interventions: SBI-087; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 6
States / cities: South Miami, Florida • Durham, North Carolina • Duncansville, Pennsylvania + 1 more

Conditions: Chronic Tendinopathy
Interventions: Adipose Stem/Stromal Cells for Enthesis/Tendon Therapy (ASSET) Injection; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Interventions: Resin microspheres containing yttrium-90 (Y-90); Device
Lead sponsor: Sirtex Medical; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 22
States / cities: Los Angeles, California • Orange, California • Miami, Florida + 16 more

Search by objective public record fields.

Bacterial Intestinal Gut Modification Around Cancer Surgery (BIG MACS) Diet

DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin

Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection

Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)

Field Administration of Stroke Therapy-Blood Pressure Lowering

Serum Potassium Prediction Using Machine Learning and Single-lead ECG

A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis

A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants

A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women

Mixed Vs Blocked Search: Four Unique Tasks

CEP-701 (Lestaurtinib) in Myelofibrosis

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

A Study of LY2484595 on the Electrical Activity of the Heart

Acoustic Stimulation Paired With Body and Cortical Stimulation for Modulating Tinnitus

Effect of Methylnaltrexone on GI Transit in Healthy Volunteers

Phase I Trial of a Single Dose of CRS3123

A Study Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET (Positron Emission Tomography)

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam

Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers

Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus

Autologous Fat Grafting for the Treatment of Chronic Tendinopathy

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients